NEW YORK (GenomeWeb) — A group of pharmaceutical companies, research groups, foundations, and the clinical sequencing firm Foundation Medicine have joined to initiate a multi-drug, multi-arm, biomarker-driven clinical trial for patients with squamous cell carcinoma called the Lung Cancer Master Protocol, or Lung-MAP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.